Vertex Pharmaceuticals Inc. (VRTX) News
Filter VRTX News Items
VRTX News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
VRTX News Highlights
- VRTX's 30 day story count now stands at 20.
- Over the past 15 days, the trend for VRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about VRTX are CF, BIO and CRSP.
Latest VRTX News From Around the Web
Below are the latest news stories about VERTEX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRTX as an investment opportunity.
Dow Jones Futures: What To Do With Market In Correction; Is Tesla The Next Leader To Crack?Friday's bounce fizzled, capping a grim week, with the S&P 500 hitting three-month lows. Tesla is close to breaking, but there are some stocks trying to hold up. |
Meta Stock Leads 5 Names Showing Resilience In Market DownturnMeta leads five resilient stocks worth watching. But investors need to be patient amid the market correction. |
2 Healthcare Stocks That Could Make You RicherThere are many ways one can become richer, from trying to buy a winning lottery ticket to pouncing on some get-rich-quick scheme. Unfortunately, none of these methods is very reliable at all, unlike investing in equities. The stock market is for those who are willing to wait, and it won't increase one's wealth substantially overnight. |
EVP and CMO Carmen Bozic Sells 5,651 Shares of Vertex Pharmaceuticals IncOn September 19, 2023, Carmen Bozic, the Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc, sold 5,651 shares of the company. |
3 Unstoppable Stocks to Buy and Hold for the Next 20 YearsBuying stocks is easy. President Joe Biden has called the next 10 years America's "infrastructure decade." There will be plenty of winners with the major global emphasis on infrastructure in the coming years. |
What Makes Vertex Pharmaceuticals Incorporated (VRTX) a Unique Investment Opportunity?Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, its Investor Class fund ARTRX returned 5.73%, Advisor Class fund APDRX posted a return of 5.78%, and Institutional Class fund APHRX returned 5.83%, compared to a […] |
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should KnowIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $358.26, marking a +1.78% move from the previous day. |
With ex-Vertex leader out as CEO, biotech makes layoffs, leaves Watertown HQA biotech once led by a longtime Vertex Pharmaceuticals executive is making layoffs and moving headquarters. |
Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded UseVertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis. |
Here's the 1 Cathie Wood Stock Most Likely to Turn $100,000 Into $1 Million Over the Next 20 YearsThere's no guarantee that any stock will be a millionaire-maker. But the chances for this one look pretty good. |